Recombinant growth hormone: A new cardiovascular drug therapy

American Heart Journal

Volumn 132, Issue 6, 1996, Pages 1244-1262

  Gomberg Maitland, Mardi ^a   Frishman, William H ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; AGING; ARTHRALGIA; CARDIOMYOPATHY; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; CROSSOVER PROCEDURE; CUSHING SYNDROME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENCEPHALOCELE; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE ANEURYSM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MUSCLE STIFFNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TINNITUS; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030465371     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90469-X     Document Type: Article

References (152)

1. Strobl JS, Thomas MJ. Human growth hormone. Pharmacol Rev 1995;46:1-34.
2. Gushing H. Partial hypophysectomy for acromegaly with remarks on the function of the hypophysis. Ann Surg 1909;50:1003-17.
3. Cushing H. The hypophysis cerebri: clinical aspects of hyper-pituitarism and of hypopituitarism. JAMA 1909;53:249-55.
4. Cushing H. The function of the pituitary body. Am J Med Sci 1910;139:473-84.
5. Evans HM, Long JA. The effect of the anterior lobe administered intraperitoneally upon growth, maturity and oestrus cycles. Anat Res 1921;21:62-5.
6. Li CH, Evans HM. The isolation of pituitary growth hormone. Science 1944;99:183-4.
7. Li CH, Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. Science 1956;124:1293-4.
8. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901-3.
9. Powell-Jackson J, Weller RO, Kennedy P, Preece MA, Whitcombe EM, Newsom-Davis J. Creutzfeldt-Jakob disease after administration of human growth hormone. Lancet 1985;2:244-6.
10. Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, et al. Direct expression in Escheriehia coli of a DNA sequence coding for human growth hormone. Nature 1979;281:544-8.
11. Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 1984;115:1952-7.
12. Plotsky PM, Vale W. Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophyseal-portal circulation of the rat. Science 1985;230:461-3.
13. Arce V, Lima L, Lois N, Rodriguez A, Diaz MJ, Tresguerres JA, et al. Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: studies with metoclopramide. Neuroendocrinology 1991;53:143-9.
14. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982;218:585-9.
15. Bohlen P, Brazeau P, Bloch B, Ling N, Gaillard R, Guillemin R. Human hypothalmic growth hormone releasing factor (GRF): evidence for two forms identical to tumor derived GRF-44-NH2 and GRF-40. Biochem Biophys Res Commun 1983;114:930-6.
16. Brazeau P, Vale W, Burgus R, Ling N, Batcher M, Rivier J, et al. Hypothalmic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
17. Casanueva FF. Physiology of growth hormone secretion and action. Endocrinol Metab Clin North Am 1992;21:483-515.
18. Laron Z: Growth hormone secretagogues: clinical, experimental and therapeutic potential. Drugs 1995;50:595-601.
19. Tapanaienen P, Knip M. Evaluation of growth hormone secretion and treatment. Ann Med 1992;24:237-47.
20. Rudd BT. Growth hormone and the somatomedins: a historical perspective and current concepts. Ann Clin Biochem 1991;28:542-55.
21. Leung W, Spencer S, Cachianes G, Hammonds RG, Collins C, Henzel WJ, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987;330:537-43.
22. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the action of the growth hormone releasing hexapeptide (GHRP). Endocrinology 1991;128:2027-35.
23. Robinson ICAF, Camignac DF, Fairhall KM. Growth hormone (GH) receptors, growth hormone binding protein, and GH: an autoregulatory system? Acta Paediatr Suppl 1993;391:22-8.
24. Dronby EC, Amburn K, Powmakn G. Circadian variation of basal growth hormone in man. J Clin Endocriu Metab 1983;57:524-8.
25. Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise and aging: the future of therapy for the frail elderly. J Am Geriat Soc 1994;42:528-35.
26. Betherat J, Bluet-Pajt MT, Eppelbaun J. Neuroendocrine regulation of growth hormone. Eur J Endocrinol 1995;132:12-24.
27. Moller N, Jorgensen JOL, Abildgard N, Orskov L, Schmitz O, Christiansen JS. Effects of growth hormone on glucose metabolism. Horm Res 1991;36(Suppl 1):32-5.
28. Iranamesh A, Veldhuis JD. Clinical pathophysiology of the somatotrophic axis in adults. Neuroendocrinology 1992;21:783-816.
29. Felsing NE, Brasel JA, Copper DM. Effect of low and high intensity exercise on circulating growth hormone in men. J Clin Endocrinol Metab 1992;73:157-62.
30. Raynaud J, Capderous A, Martineaud J, Bordachar J, Durand J. Intersubject variability in growth hormone time course during different types of work. J Appl Physiol 1983;55:1682-7.
31. Yarasheski KE. Growth hormone effects on metabolism, body composition, muscle mass, and strength. Circulation 1994;22:285-312.
32. Finkelstein JW, Roffward HP, Boyar RM, Kream J, Hellman L. Age related change in the 24 hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972;35:665-70.
33. Ho KY, Valdhuis JD, Johnson ML, Farlanetto R, Evans WS, Alberting MM, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth secretion in man. J Clin Invest 1988;81:968-75.
34. Rudman D, Kutner MH, Rogers MC, Lubin MF, Fleming Ga, Bain RP. Impaired growth hormone secretion in the adult population. Relation to age and adiposity. J Clin Invest 1981;67:1361-9.
35. Rudman D. Growth hormone, body composition and aging. J Am Geriatr Soc 1985;33:800-7.
36. Florini JR, Prinz PM, Vitiello MV, Hintz RL. Somatomedin-C levels in healthy young and old men: relationship to peak and 24 hour integrated levels of growth hormone. J Gerontol 1985;40:2-7.
37. Salmon WD, Daughaday H. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Cliu Med 1957;49:825-36.
38. Daughaday WH, Karl IE, Karl MM. A failed assay opened a new door in growth hormone research. Endocrinology 1992;130:565-6.
39. Marquart M, Todaro GJ, Henderson LE, Oroszlans S. Purification and primary structure of a polypeptide with multiplication-stimulating activity from rat liver cell cultures: homology with insulin-like growth factor II. J Biol Chem 1981;256:6859-63.
40. Daughaday WH, Hall K, Raben M, Salmon WD, Van den Drande JL, Van Wyk JJ. A proposed designation for the sulphation factor. Nature 1972;235:102.
41. Rinderknect E, Humbel RE. The amino acid sequence of insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978;253:2769-76.
42. Rinderknect E, Humbel RE. Primary structure of human insulin-like growth factor II. FEBS Lett 1978;89:283-6.
43. Van Wyk JJ, Underwood LE, Hintz RL, Clemmons DR, Voina SJ, Weaver RP. The somatomedins: a family of insulinlike hormones under growth hormone control. Recent Prog Horm Res 1974;30:259-94.
44. Tricoli JV, Pall LB, Scott J, Bell GI, Shows TB. Localization of insulin-like growth factor genes to human chromosomes 11 and 12. Nature 1984;310:784-6.
45. Rutanen EM, Pekonen F. IGF and their binding proteins. Acta Endocrinology 1990;123:7-13.
46. Landin-Wilhelmsen K, Wuhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg P-A, et al. Serum insulin-like growth factor I in a random population sample of men and women: relationship to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994;41:351-7.
47. Yamamoto H, Sohmiya M, Oka N, Kato Y. Effects of aging and sex on plasma IGF I levels in normal adults. Acta Endocrinol (Copenh) 1991;124:497-500.
48. Poelman ET, Copeland KC. Influence on physical activity on IGF I in healthy younger and older men. J Clin Endocrinol Metab 1990;71: 1468-73.
49. Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991;36(Suppl 1):44-8.
50. Moller J, Jorgensen JOL, Moller N, Hansen KW, Pedersen EB, Christiansen JS. Expansion of extracellular volume and suppression of atrial natriuretic peptide after growth hormone administration in normal man. J Clin Endocrinol Metab 1991;72:768-72.
51. Czernichow P. Growth hormone administration and carbohydrate metabolism. Horm Res 1993;39:102-3.
52. Keller U, Miles JM. Growth hormone and lipids. Horm Res 1991; 36(Suppl 1):36-40.
53. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson J-A, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992;89:6983-7.
54. Saloman F, Cuneo R, Sonksen PH. Growth hormone and protein metabolism. Horm Res 1991;36(Suppl 1):41-3.
55. Bouillon R. Growth hormone and bone. Horm Res 1991;36(Suppl 1):49-55.
56. Grunfeld C, Sherman BM, Cavalieri RR. The acute effects of human growth hormone administration on thyroid function in normal men. J Clin Endocrinol Metab 1988;67:1111-4.
57. Wit JM, Kooijman R, Rikers GT, Zegers BJM. Immunologic findings in growth hormone-treated patients. Horm Res 1993;39:107-10.
58. Theusen L, Christiansen JS, Sorensen KE, Jorgensen JOL, Orskov H, Henningsen P. Increased myocardial contractility following growth hormone administration in normal man: an echocardiographic study. Dan Med Bull 1988;35:193-6.
59. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, et al. Insulinlike growth faetor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715-21.
60. Vetter U, Kupferschmid C, Lang D, Pentz S. Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiomyocytes in vitro. Basic Res Cardiol 1988;83:647-54.
61. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Laugo RP, Bernstein JA, et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994;89: 799-809.
62. Friberg P, Adams MA, Isgaard J, Wickmann A, Wahlander H. Right but not left ventricular insulin-like growth factor I and growth hormone receptor levels increase after induction of volume overload [abstract]. Hypertension 1993;22:418.
63. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. Circulation 1996;93:800-9.
64. 2+ handling and enhanced cardiac performance. Circ Res 1996;79:227-36.
65. Sacca L, Cittadina A, Fazio S. Growth hormone and the heart. Endocrin Rev 1994;15:555-73.
66. Hejmancik MR, Bradfield JY, Herrmann GR. Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med 1951;34:1445-56.
67. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1979;34:1-16.
68. McGuffin WL, Sherman BM, Roth J, Gorden P, Kahn CR, Roberts WC, et al. Acromegaly and cardiovascular disorders: a prospective study. Ann Intern Med 1974;81:11-8.
69. Fazio S, Cittadini A, Cuocolo A, Merola B, Sabatini D, Colao A, et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994;79:441-6.
70. Fazio S, Cittadini A, Sabatini D, Merola B, Colao AM, Biondi B, et al. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study. Eur Heart J 1993;14:26-33.
71. Evans HM, Simpson HE, Li CH. The gigantism produced in normal rats by injection of pituitary growth hormone. Growth 1948;12:15-32.
72. Beznak M. The restoration of cardiac hypertrophy and blood pressure in hypophyseetomized rats by large doses of lyophilized anterior pituitary and growth hormone. J Physiol (Lond) 1954;124:64-74.
73. Prysor-Jones RA, Jenkins JS. Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle. J Endocrinol 1980;85:75-82.
74. Penney DG, Dunbar JC Jr, Baylerian MS. Cardiomegaly and haemodynamics in rats with a transplantable growth hormone-secreting tumour. Cardiovasc Res 1985;19:270-7.
75. Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 1990;86:507-15.
76. Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen F, Hoffmann C, Mercadier J-J. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Cire Res 1993;72:57-64.
77. Xu X, Best PM. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am J Physiol 1991;260:H935-42.
78. Hirsh EZ, Sloman JG, Martin FIR. Cardiac function in acromegaly. Am J Med Sci 1969;257:1-8.
79. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
80. Sassayama S, Ross J Jr, Franklin D, Bloor CM, Dilley RB. Adaptations of the left ventricle to chronic pressure overload. Circ Res 1976;38:172-8.
81. Theusen L, Christsen J, Weeke J, Orskov H, Henningsen P. A hyperkinetic heart in uncomplicated active acromegaly. Acta Med Scand 1988;223:337-43.
82. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analog of somatostatin with prolonged action. Life Sci 1982;31:1133-40.
83. Lim MS, Barkan AL, Buda AJ. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hyper-secretion. Ann Intern Med 1992;117:719-26.
84. Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993;77:790-3.
85. Rosen T, Bengtsson B. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-8.
86. Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson B-A. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol 1993;129:195-200.
87. Christiansen JS, Jorgensen JOL, Kristensen BO, Moller J, Theusen L. Cardiovascular effects of growth hormone: with special reference to growth hormone replacement therapy. Acta Paediatr Suppl 1992; 383:40-2.
88. Amato G, Carella C, Fazio S, LaMontagna G, Cittadini A, Sabatini D, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77:1671-6.
89. Shahi M, Beshyah S, Hackett D, Sharp P, Johnston D, Foale R. Cardiac structure and function in growth hormone deficiency [abstract]. Br Heart J 1991;66:58.
90. Caidahl K, Eden S, Bengtsson B-A. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994;40:393-400.
91. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994;267:E219-25.
92. Schwartz RS. Trophic factor supplementation: effect of the age-associated changes in body composition. J Gerontol 1995;50A(Special Issue): 151-6.
93. Cuneo C, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults: I. effects on muscle mass and strength. J Appl Physiol 1991;70:688-94.
94. Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth hor mone treatment in growth hormone-deficient adults: II. effects on exercise performance. J Appl Physiol 1991;70:695-700.
95. Cuocolo A, Nicolai E, Colao A, Longobardi S, Cardei S, Fazio S, et al. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur J Nucl Med 1996;23:390-4.
96. Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R, Johnston DG. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994;130:451-8.
97. Whitehead HM, Boreham C, Mcllrath EM, Sheridan B, Kennedy L, Atkinson AB, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13 month placebo controlled crossover study. Clin Eudocrinol 1992;36:45-52.
98. Jorgensen JOL, Pedersen SA, Thuesen L, Jorgensen J, IngemannHansen T, Skakkebaek NE, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989;1:1221-5.
99. Beshayah SA, Shahi M, Foale R, Johnston DG. Cardiovascular effect of prolonged GH replacement in adults. J Intern Med 1995;237:36-42.
100. DeBoer H, Blok G-J, Van Der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrinol Rev 1995;16:63-86.
101. Brown L, Wyse B, Sernia C. Adrenoceptor-mediated cardiac and vascular responses in genetically growth hormone-deficient rats. Biochem Pharmacol 1993;45:2223-9.
102. Cittadini A, Stromer H, Katz SE, Grossman JD, Morgan JP, Douglas PS. Growth hormone modulates cardiac function and β-adrenergic response [abstract]. Circulation 1995;92(Suppl I):I-184.
103. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
104. Hamsten A, DeFaire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
105. Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 1994;14:434-7.
106. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN, Johnston DG. Detection of premature atherosclerosis by high-resolution ultrasouography in symptom-free hypopituitary adults. Lancet 1992;340:1188-92.
107. Merimee TJ, Hollander W, Fineberg SE. Studies of hyperlipidemia in the HGH-deficient state. Metab 1972;21:1053-61.
108. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-803.
109. Jorgensen JOL, Moller J, Alberti KGMM, Schmitz O, Christiansen JS, Orskov H, et al. Marked effects of sustained low growth hormone (GH) levels on day-to-day fuel metabolism: studies in GH-deficient patients and healthy untreated subjects. J Clin Endocrinol Metab 1993;77:1589-96.
110. Beauville M, Harant I, Crampes F, Riviere D, Tauber MT, Tauber JP, et al. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am J Physiol 1992;263:E467-72.
111. Snel YE, Brummer RJ, Doerga ME, Zelissen PM, Bakker CJ, Hendriks MJ, et al. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects. Am J Clin Nutr 1995;61:1290-4.
112. DeBoer H, Blok GJ, Voerman HJ, Phillips M, Schouten JA. Serum lipidlevels in growth hormone deficient men. Metabolism 1994;43:199-203.
113. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson B-A. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL concentrations. Arterioscler Thromb 1993;13:296-301.
114. Frustaci A, Pesone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992;97:503-11.
115. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sonksen PH. Cardiac failure responding to growth hormone. Lancet 1989;1:838-9.
116. Moller J, Jorgensen JOL, Lauersen T, Frystyk J, Naeraa RW, Orskov H, et al. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters. Clin Endocrinol 1993;39:403-8.
117. Jorgensen JOL, Flyvbjerg A, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. Dose-reponse studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab 1988;67:36-40.
118. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, et al. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994;94:1126-33.
119. Cuneo RC, Salomon F, Wilmshurst P, Byrne C, Wiles CM, Hesp R, et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci 1991;81:587-92.
120. Bengtsson B-A, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, et al. Treatment of adults with growth hormone (GH) deficiency with recombinaut human GH. J Clin Endocrinol Metab 1993;76:309-17.
121. Bjork A, Jonsson B, Westphal O, Levin J-E. Quality of life of adults with growth hormone deficiency: a controlled study. Acta Paediatr Scand Suppl 1989;356:55-9.
122. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl 1989;356:70-2.
123. Binnerts A, Swart RG, Wilson JHP, Hoogerbrugge N, Pols HAP, Birkenhager JC, et al. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate, and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992;37:79-87.
124. Almquist O, Thoren M, Saaf MM, Eriksson O. Effects of growth hormone substitution on mental performance in adults with growth hormone deficiency: a pilot study. Psychoneuroendocrinology 1986;11: 347-52.
125. Wilson D. Clinical action of growth hormone. Endocrinol Metab Clin North Am 1992;21:519-37.
126. Ritzen EM. Does growth hormone increase the risk of malignancies? Horm Res 1993;39:99-101.
127. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14.
128. Guistina A, Lorusso R. Borghetti V, Bugari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy. Am Heart J 1996;131:620-2.
129. Yang R, Bunting S, Gillett N, Clark R, Hong Kui J. Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92:262-7.
130. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharm 1995;26:420-5.
131. Arnand I, Chandrashekhar Y, Ferrari R, Poole-Wilson P, Harris P. Growth hormone in syndromes of chronic congestive heart failure [abstract]. Circulation 1992;86(4):I-688.
132. Hasenfuss G, Mulieri LA, Leavitt BJ, Alien PD, Holubarsch C, Just H, et al. Contractile protein function in failing and nonfailing human myocardium. Basic Res Cardiol 1992;87:107-16.
133. Arnolda L, Brosnan J, Rajagopalan B, Radda GK. Skeletal muscle metabolism in heart failure in rats. Am J Physiol 1992;261:H434-42.
134. Massie B, Conway M, Yonge R, Frostick S, Ledingham J, Sleight P, et al. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation 1987;76:1009-19.
135. Cerek B, Shah PK. Complicated acute myocardial infarction. Cardiol Clin 1991;9:569-93.
136. Castagnino HE, Toranzos FA. Ventricular aneurysms: a geometrical-dynamical model. Jpn J Exp Med 1989;59:89-102.
137. Castagnino HE, Toranzos FA, Milei J, Weiss V, Beigelman R, Sarchi MI, et al. Preservation of the myocardial collagen framework by human growth hormone in experimental infarctions and reduction in the incidence of ventricular aneurysms. Int J Cardiol 1992;35:101-14.
138. Castagnino HE, Milei J, Toranzos FA, Weiss V, Biegelman R. Bivalent effects of human growth hormone in experimental myocardial infarets. Jpn Heart J 1990;31:845-51.
139. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.
140. Thompson JL, Butterfield GE, Marcus R, Hintz RL, Van Loan M, Ghiron L, et al. The effects of recombinant human insulin-like growth factor-1 and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995;80:1845-52.
141. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ, Hintz RL, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990;70: 519-27.
142. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 1984;289:1257-61.
143. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjornstorp P, Tibblin G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 1984;288:1401-4.
144. 137a. Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GAW, Schambelan M, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996;124:708-16.
145. Kaplan SL. The newer uses of growth hormone in adults. Adv Intern Med 1993;38:287-301.
146. Lamberts SWJ, Valk NK, Binnerts A. The use of growth hormone in adults: a changing scene. Clin Endocrinol 1992;137:111-5.
147. Sassolas G. Potential therapeutic applications of growth hormone in adults. Horm Res 1994;42:72-8.
148. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 1993;91: 391-6.
149. Iovino M, Monteleone P, Steardo L. Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging. J Clin Endocrinol Metab 1989;69:910-3.
150. Corpas E, Hartman SM, Pincyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone (1-29) twice daily reverses the decreased GH and insulin like growth factor-1 levels in old men. J Clin Endocrinol Metab 1992;75:530-5.
151. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, et al. Effect of 15 day treatment with growth hormone-releasing hormone alone or combined with different doses of arginine on the reduced somatotrope responsiveness to the neurohormone in normal aging. Eur J Endocrinol 1995;132:32-6.
152. Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 1992;74:1378-84.